
Keywords: CI، شاخص ترکیبی; prostatic neoplasms; prostatic neoplasms; castration-resistant; dutasteride; MDV 3100; antineoplastic combined chemotherapy protocolsADT, androgen deprivation therapy; AR, androgen receptor; BPH, benign prostatic hyperplasia; CI, combination index; CRPC,